Cigna Corporation

🇺🇸New York Stock Exchange

Articles

30
Show Summary
Show Bulletpoints
Detailed View
Bullish +75

ROUNDUP: Cigna Group Lifts FY26 Adj. Profit View After Q1 Results Rise

📈 Fiscal 2026 outlook raised to $30.35 per share on portfolio growth.

💰 Q1 net income surged 47% to $1.65 billion, up from $1.32 billion last year.

🏥 Adjusted operations income jumped 12% driven by Healthcare and Evernorth units.

📈 Cigna Group raised its full fiscal 2026 outlook for adjusted income from operations to at least $30.35 per share.

📊 This represents an increase from the previous guidance of $30.25 per share, driven by growth across its diverse business portfolio.

💰 First quarter net income rose to $1.65 billion or $6.26 per share compared to $1.32 billion or $4.85 per share last year.

🏥 Adjusted income from operations for the first quarter increased by 12% year-over-year to $2.06 billion or $7.79 per share.

📉 The growth in adjusted income was primarily fueled by higher contributions from Cigna Healthcare and Evernorth Health Services.

💵 Total revenue climbed 4.6% to $68.494 billion, mainly driven by expansion in the Evernorth Health Services unit.

👥 The company reported a total of 185.47 million customer relationships as of March 31, 2026, up from 182.21 million last year.

🏢 Total medical customers grew to 18.33 million, though pharmacy customers decreased to 121.02 million during the period.

⚠️ The earnings release mentioned plans to exit its individual exchange business by the end of the year while undertaking a strategic review of eviCore.

📉 Shares traded slightly lower in pre-market activity at $290.00, down 0.85 percent despite the positive earnings report.

🏦 Analyst firms including Cantor Fitzgerald and Mizuho recently raised their price targets for Cigna following the Q1 results.

🔝 Evernorth Health Services was specifically highlighted as a primary driver of both revenue and operational growth in the first quarter.

Bullish Signals
  • Cigna Group raised its fiscal 2026 adjusted income from operations outlook to at least $30.35 per share, up from the previous expectation of $30.25 per share.
  • First quarter shareholders' net income surged to $1.65 billion, or $6.26 per share, representing significant year-over-year growth driven by strong performance across the enterprise.
  • Adjusted income from operations for the first quarter increased by 12% to $7.79 per share compared to the same period last year.
  • Total revenue grew 4.6% year-over-year to $68.494 billion, primarily driven by expansion in the Evernorth Health Services unit.
  • The company's diversified portfolio of businesses continues to drive growth across its segments, reinforcing confidence in future profitability.
  • Analyst sentiment remains positive with Mizuho raising its Cigna stock price target to $330 following the Q1 results and strategic outlook.
Risk Factors
  • In pre-market activity, Cigna shares were trading at $290.00, down 0.85 percent from the previous session.
  • The company announced plans to exit its individual exchange business by the end of the year, signaling a contraction in that specific segment.
Bullish +63

Here's What to Expect From Cigna Group's Next Earnings Report

📅 Cigna Group reports Q1 2026 earnings Thursday, April 30, before market open.

💰 Analysts forecast quarterly EPS of $7.57, up 12.3% year-over-year.

🏆 18 of 23 analysts rate CI "Strong Buy" with $338 average price target.

📈 Stock down 13% over 52 weeks despite recent rally and strong Q4 beat.

🏢 The Cigna Group (CI), headquartered in Bloomfield, Connecticut, operates as a major provider of insurance and pharmacy benefit management services.

📅 Wall Street expects CI to release its fiscal first-quarter 2026 earnings results before the market opens on Thursday, April 30.

💰 Analysts forecast quarterly EPS of $7.57, representing a 12.3% year-over-year increase from $6.74 in the same period last year.

📊 CI has beaten Wall Street bottom-line estimates for the last four consecutive quarters, including recent Q4 earnings that surpassed consensus by $0.20 per share.

🔮 For the fiscal year ending December 2025, analysts project a profit of $30.32 per share, a slight increase from $29.84 in fiscal 2025.

📈 Long-term growth expectations remain strong, with estimated EPS reaching $33.32 in fiscal 2027 for a 9.9% year-over-year gain.

📉 Despite positive earnings forecasts, CI stock has fallen 13% over the past 52 weeks, significantly underperforming both the S&P 500 and health care sector ETFs.

🎉 Shares recently rallied 4.7% on February 5 following Q4 results that saw revenue jump 10.4% to $72.5 billion and adjusted EPS rise 21.7%.

🚀 Management cited robust expansion in EverNorth specialty services, biosimilar adoption, and operational discipline as key drivers of recent performance.

🏆 Investor sentiment is highly bullish, with 18 out of 23 analysts rating CI as "Strong Buy" and two rating it as "Moderate Buy."

💵 The average Wall Street price target for CI stands at $338.32, suggesting roughly 21.5% potential upside from current trading levels.

Bullish Signals
  • Cigna Q1 2026 profit expected at $7.57/share, up 12.3% YoY.
  • Company beat bottom-line estimates for four consecutive quarters.
  • Fiscal year 2024 analysts project $30.32 EPS, up 1.6% from prior year.
  • EPS forecasted to rise another 9.9% to $33.32 in fiscal 2027.
  • Shares surged 4.7% after Q4 revenue jumped 10.4% to $72.5B.
  • Adjusted Q4 EPS grew 21.7% to $8.08, beating estimates by $0.20.
  • Strong business growth and operational discipline supported recent results.
  • Wall Street rates 'Strong Buy' with majority of analysts recommending buy.
  • Mean price target of $338.32 offers 21.5% upside from current levels.
Risk Factors
  • Stock down 13% in 52 weeks.
  • Lags S&P 500 up 25.1%.
  • Underperforms XLV up 7.6%.
  • Three of 23 analysts suggest 'Hold'.
  • Three recommend 'Moderate Buy'.
Bullish Signals
  • Analysts expect Cigna Group (CI) to report a profit of $7.57 per share in fiscal Q1 2026, representing a 12.3% increase from the year-ago quarter of $6.74.
  • The company has topped Wall Street's bottom-line estimates in each of the last four quarters, with previous earnings of $8.08 per share exceeding forecasts by 2.7%.
  • For the current fiscal year ending in December, analysts project CI to report a profit of $30.32 per share, reflecting a 1.6% increase from $29.84 in fiscal 2025.
  • EPS is forecasted to grow an additional 9.9% year-over-year to reach $33.32 in fiscal 2027.
  • Shares of CI surged 4.7% on Feb. 5 following better-than-expected Q4 results, where revenue jumped 10.4% year over year to $72.5 billion against consensus expectations of $69.9 billion.
  • Adjusted EPS advanced 21.7% from the year-ago quarter to $8.08 in Q4, surpassing the Wall Street estimate of $7.88.
  • Robust expansion in EverNorth specialty and care services, successful biosimilar adoption, and operational discipline across health benefits business supported recent results.
  • Wall Street analysts hold a 'Strong Buy' rating overall with 18 out of 23 analysts recommending 'Strong Buy', two indicating 'Moderate Buy', and three suggesting 'Hold'.
  • The mean price target for CI is $338.32, indicating 21.5% potential upside from current trading levels.
Risk Factors
  • Cigna Group (CI) has declined 13% over the past 52 weeks, considerably underperforming both the S&P 500 Index's ($SPX) 25.1% return and the State Street Health Care Select Sector SPDR ETF's (XLV) 7.6% uptick over the same time frame.
  • Three out of 23 analysts covering CI suggest a 'Hold' rating, with three recommending 'Moderate Buy', indicating potential skepticism from some Wall Street firms despite the overall positive sentiment.
Neutral 0

Cigna Group stock rises Wednesday, still underperforms market

📈 Cigna Group shares rose 1.21% to $277.56 on Wednesday.

📉 Stock remains 20.70% below its 52-week high of $350.00.

🏦 S&P 500 advanced 2.51% to close at 6,782.81.

📈 Cigna Group (CI) shares rose 1.21% on Wednesday to $277.56 amid a broadly positive market session.

📉 The stock remains 20.70% below its 52-week high of $350.00, which was set on May 2nd.

🏦 The S&P 500 Index advanced 2.51% to close at 6,782.81 during the trading period.

📉 The Dow Jones Industrial Average climbed 2.85%, ending the day at 47,909.92.

Bullish Signals
  • Cigna shares rose 1.21% as S&P 500 and Dow climbed.
  • Stock hit $350 high on May 2nd, showing strong upward potential.
Risk Factors
  • Stock down 20.7% from 52-week high of $350 despite gains.
  • Shares rose just 1.21% vs S&P 500's 2.51% rise.
  • Price below May peak suggests limited short-term upside.
Bullish Signals
  • Cigna Group shares advanced 1.21% to $277.56 on Wednesday, reflecting positive market sentiment as the S&P 500 Index rose 2.51% and the Dow Jones Industrial Average climbed 2.85%.
  • The stock achieved a high of $350.00 on May 2nd during the trading year, demonstrating its potential to reach new peaks in the future.
Risk Factors
  • Stock remains significantly underperforming the broader market, closing 20.70% below its 52-week high of $350.00 despite a positive trading session.
  • Cigna Group shares advanced only 1.21% to $277.56 while major benchmarks like the S&P 500 rose 2.51%, highlighting continued underperformance relative to market peers.
  • Current share price of $277.56 represents a substantial decline from the May 2nd peak, suggesting limited upside momentum in the short term.
Bullish +75

Cigna (CI) Gets a Buy from Bernstein

📈 Bernstein analyst sets Cigna price target at $358 with Buy rating.

💰 Quarterly revenue reached $72.47 billion, up from prior year's $65.65B.

⚠️ Net profit decreased to $1.23 billion compared to $1.42 billion last year.

📈 Bernstein analyst Lance Wilkes maintains a Buy rating on Cigna (CI) and sets a new price target of $358.00.

💰 The company reported quarterly revenue of $72.47 billion for the quarter ending December 31, up from $65.65 billion the prior year.

⚖️ Net profit decreased to $1.23 billion compared to $1.42 billion in the same period last year.

🤝 The wider street consensus rates Cigna as a Strong Buy with an average analyst price target of $342.62.

🩺 Analyst Lance Wilkes covers the Healthcare sector, including stocks such as Centene and CVS Health.

📊 TipRanks data indicates Wilkes has an average return of -8.7% with a 32.67% success rate on recommended stocks.

⚠️ Content is syndicated from third-party sources, including paid content and unreviewed press releases.

Bullish Signals
  • Analyst maintained Buy rating on Cigna with price target of $358.
  • Street consensus shows Strong Buy rating with average price target of $342.62.
  • Cigna reported quarterly revenue of $72.47B and net profit of $1.23B.
Bullish Signals
  • Bernstein analyst Lance Wilkes maintained a Buy rating on Cigna (CI) with a price target of $358.00, indicating strong investor confidence.
  • The Street suggests a Strong Buy analyst consensus rating for Cigna with an average price target of $342.62 across Wall Street analysts.
  • Cigna reported quarterly revenue of $72.47 billion and a net profit of $1.23 billion for the quarter ending December 31, demonstrating solid financial performance.
Risk Factors
  • Analyst Lance Wilkes at Bernstein has an average return of -8.7% on recommended stocks, suggesting the quality of his past calls may be subpar.
Bullish +75

Cigna: Flashing A Buy For Dividend Growth And Deep Value

📈 Cigna Group maintains 'Buy' rating with double-digit EPS growth expected from 2027.

💊 Growth drivers include pharmacy expansion and aggressive share buybacks.

📊 Stock trades at 8.5x forward P/E, a 29% discount to fair value.

🤲 Low-20% payout ratio supports dividend safety with robust growth capacity.

📈 Cigna Group (CI) maintains a 'Buy' rating with catalysts for double-digit adjusted income per share growth expected to resume in 2027 and beyond.

💊 Growth drivers include expansion in the pharmacy segment, biosimilar adoption, behavioral health services, and aggressive share buybacks.

📊 The stock trades at an 8.5x forward P/E, representing a 29% discount to fair value.

🏦 Investors project a potential 17% annual total return for Cigna through the year 2031 based on current valuation metrics.

🤲 Dividend safety is highlighted by a low-20% payout ratio and an A+ Quant grade, indicating robust capacity for dividend growth.

👨‍💼 Scott Kaufman of Dividend Kings describes the company as having the financial anatomy typical of high-quality dividend growers with dominant market position.

⚠️ The author discloses a beneficial long position in Cigna shares but notes they did not receive compensation specifically for this article.

⚖️ Seeking Alpha and its third-party analysts disclaim that past performance is no guarantee of future results.

📉 No formal investment recommendation or suitability advice is given regarding whether the stock fits an individual investor's specific portfolio needs.

🔒 Seeking Alpha clarifies it is not a licensed securities dealer, broker, or US investment adviser.

Bullish Signals
  • Cigna Group remains a Buy rating with double-digit income growth expected from 2027.
  • Pharmacy segment and share buybacks drive topline and margin growth.
  • Shares trade at 8.5x forward P/E, a 29% discount supporting 17% annual returns through 2031.
  • Low-20% payout ratio supports continued, accelerating dividend growth.
Risk Factors
  • No negative points or risks were identified.
  • Analyst holds beneficial long position in Cigna shares.
Bullish Signals
  • Cigna Group remains a Buy rating with catalysts for double-digit adjusted income per share growth expected to resume in 2027 and beyond.
  • Pharmacy segment, biosimilar adoption, behavioral health expansion, and aggressive share buybacks are driving both topline and margin growth.
  • Shares trade at an 8.5x forward P/E, representing a 29% discount to fair value, which supports a projected 17% annual total return through 2031.
  • Dividend safety is robust with a low-20% payout ratio and A+ Quant grade, positioning CI for continued, accelerating dividend growth.
Risk Factors
  • No negative points or risks were identified in this article; the entire text is positive, focusing on buy recommendations, growth catalysts, undervaluation, dividend safety, and analyst credentials.
  • The article contains an analyst disclosure stating they have a beneficial long position in Cigna shares, which creates a potential conflict of interest that could bias the bullish recommendation.
Somewhat Bullish +50

2026 Just Capital rankings: See the companies on the annual list of corporate leaders

🏆 Just Capital released 2026 rankings of America's most ethical companies.

💼 HP Inc., Union Pacific, and Hewlett Packard Enterprise led the Russell 1000.

📊 Analysis covered 17 issues across five stakeholder groups using 85+ data points.

🌍 Investors now seek ethical performance that balances people and profits.

🏆 Just Capital released its 2026 annual rankings identifying the "most just" companies in America using public polling data.

🔍 The methodology analyzes 17 core issues across five stakeholder groups: workers, communities, shareholders, customers, and the environment.

⚠️ Corporate leaders are facing unprecedented uncertainty regarding geopolitics, inflation, and AI while shifting away from traditional ESG commitments.

💼 The Russell 1000 universe was ranked, with HP Inc., Union Pacific, and Hewlett Packard Enterprise securing the top three spots.

🩺 Cigna Group (CI) ranked 13th on the list in this year's edition of Just Capital corporate leaders.

📉 Investors are adapting by moving capital into sectors that balance ethical considerations with strong bottom-line performance for workers and communities.

🧮 The annual research process evaluated over 85 overall data points and 36 sector-specific data points to determine final standings.

💡 Companies are pivoting investments to maximize future returns while avoiding political controversy in their sustainability strategies.

Bullish Signals
  • Cigna Group (CI) ranked #13 most just by Just Capital.
  • Analysis covered over 85 data points across five stakeholder groups.
  • CI joins top leaders like HP Inc and Accenture on the list.
  • Top rankings achieved despite challenging economic landscape and inflation.
  • Shift toward 'just' investments maximizes future returns for all stakeholders.
Risk Factors
  • Trump era retreat from ESG/DEI creates compliance risks for firms like Cigna.
  • Geopolitics and AI adoption pressure bottom lines despite investment commitments.
  • 2026 rankings use subjective polling potentially misaligned with financial performance.
  • Stakeholder priority shifts may dilute shareholder value and increase costs.
Bullish Signals
  • The Cigna Group (CI) has been recognized as the #13 most just company on the 2026 Just Capital rankings, highlighting its strong standing in ESG and DEI despite recent industry shifts.
  • Just Capital's rigorous methodology evaluated over 85 data points across five stakeholder groups, including workers, communities, shareholders, customers, and the environment to determine the list.
  • The ranking identifies top-tier corporate leaders like HP Inc (Rank 1), Union Pacific (Rank 2), and Accenture (Rank 9) alongside CI, validating CI's position among America's best performers.
  • The recognition comes amidst a challenging economic landscape with geopolitical uncertainty and inflation, suggesting these companies are successfully navigating complex challenges while maintaining high standards.
  • There is an emerging shift where 'just' investments are being made to maximize future returns for all stakeholders, from investors to workers and communities, positioning CI as a leader in this strategic evolution.
Risk Factors
  • Companies are retreating from ESG and DEI initiatives during the second Trump administration, potentially creating reputational and compliance risks for ranked firms like Cigna.
  • Corporate boardrooms face heightened uncertainty from geopolitics, inflation, and AI adoption, which could pressure bottom-line delivery despite 'just' investment commitments.
  • The 2026 rankings are based on public polling that prioritizes issues contributing to 'just business behavior,' a subjective metric that may not align with traditional financial performance standards.
  • Investors face shifting priorities toward maximizing returns for stakeholders from workers to communities, which could dilute shareholder value and increase cost structures.
  • The article notes pressure mounts to deliver on the bottom line while steering clear of politics, suggesting companies must navigate conflicting demands that could impact strategic focus.
Bullish +65

Bernstein Upgrades The Cigna Group (CI) From “Market Perform” to “Outperform”

📈 Bernstein upgrades Cigna to Outperform with a $358 price target.

💰 Management projects 2026 income of $30.25 per share.

👋 Investors remain confident in new CEO Brian Evanko despite transition.

⚖ Confidence driven by PBM reform, settlements, and model changes.

📈 Bernstein upgraded The Cigna Group (CI) from "Market Perform" to "Outperform."

💵 Analysts set a $358 price target for the stock following the upgrade.

🏥 Management reiterated its 2026 projection of at least $30.25 per share in consolidated adjusted income from operations.

💊 The company expects Evernorth's pre-tax adjusted income to be at least $6.9 billion.

🦠 Cigna Healthcare is projected to generate at least $4.5 billion in pre-tax adjusted income from operations.

📉 Analysts slightly raised EPS estimates for the years 2027 through 2030 while keeping the 2026 estimate unchanged.

⚖️ Investor confidence is driven by PBM reform, FTC settlements, announced model changes, and guided economic impacts.

👋 CEO Cordani's retirement was seen as a surprise, but analysts remain confident in new CEO Brian Evanko.

🌐 Cigna operates globally offering pharmacy benefit management, specialty pharmacy, care delivery, and medical insurance solutions.

📉 The article notes that while CI is an investment, AI stocks may offer greater upside potential with less risk.

📄 Disclosure indicates none and encourages readers to follow Insider Monkey on Google News.

Bullish Signals
  • Bernstein upgraded The Cigna Group (CI) from 'Market Perform' to 'Outperform', reflecting strong analyst confidence in the stock's prospects.
  • The firm established a $358 price target, indicating significant upside potential relative to current market prices.
  • Analysts expect the company's stock multiple to increase over time due to positive drivers such as PBM reform bill impacts and favorable economic conditions.
  • Management slightly raised EPS estimates for 2027-2030, signaling long-term growth visibility and operational stability.
  • The company reiterated its 2026 projection with an estimated consolidated adjusted income from operations of at least $30.25 per share.
  • Cigna Healthcare is projected to generate at least $4.5 billion in pre-tax adjusted income from operations for 2026, reinforcing core business strength.
  • Management maintained stability across major sectors by restating Evernorth's projection for at least $6.9 billion in pre-tax adjusted income from operations.
  • Analysts at JPMorgan Chase & Co. expressed confidence in the company's new leadership transition under CEO Brian Evanko following the departure of Cordani.
Risk Factors
  • Analysts at JPMorgan Chase & Co. noted that the retirement of CEO Cordani came as a surprise, raising questions about leadership continuity despite their expressed confidence in new CEO Brian Evanko.
  • While Bernstein upgraded the stock, analysts from other firms argue that AI stocks currently offer greater upside potential and carry less downside risk than Cigna (CI).
  • The article suggests that investors looking for short-term gains driven by Trump-era tariffs or onshoring trends should consider AI stocks instead of CI.
  • Despite the 'Outperform' rating and price target increase, the stock is presented as a secondary option compared to emerging AI equities in the current market landscape.
Somewhat Bullish +45

Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?

🏢 Cigna operates via Healthcare and Evernorth segments with a $68.8B market cap and forward P/E of 8.61x.

📉 Shares dropped 3.4% YTD while beating earnings estimates for four consecutive quarters.

⚡ Adjusted income rose 4% in 2025 as revenue grew 3.5% to $284.4 billion by 2026.

💸 Expenses escalated significantly, with total benefits rising 12% despite improved SG&A ratios.

🩺 Investors face margin pressure from escalating costs while the dividend yield remains robust.

🏢 Cigna operates through two main segments: Cigna Healthcare and Evernorth Health Services, offering medical plans and pharmacy solutions.

💰 The company has a market capitalization of $68.8 billion and trades with a forward P/E ratio of 8.61x, which is lower than the industry average of 13.45x.

📉 Shares have lost 3.4% year-to-date, yet this loss is less severe than the industry’s 13.5% decline over the same period.

🔒 Cigna holds a Zacks Rank #3 (Hold) and carries a Value Score of A based on current market analysis.

📈 The consensus estimate for 2026 earnings is pegged at $30.29 per share, suggesting a 1.5% year-over-year increase.

💵 Estimated revenue for 2026 is pinned at $284.4 billion, indicating 3.5% year-over-year growth.

📊 The company beat earnings estimates in each of the trailing four quarters, with an average surprise of 2.7%.

⚡ Adjusted income from operations rose 4% in 2025, driven by strong growth in the Evernorth Health Services segment.

🏥 Evernorth Health Services’ adjusted revenues increased 16% in 2025 to $235 billion as the company adopted a new pharmacy benefits model.

💸 Adjusted SG&A expense ratio dropped to 5.0% in 2025 due to business mix shifts and digital transformation efforts.

🤝 The quarterly dividend was increased to $1.56 per share in early 2026 from $1.51 in 2025, signaling confidence in long-term cash flow.

📉 Total benefits and expenses escalated 27% in 2024 and 12% in 2025, with the medical cost ratio deteriorating to 84.4%.

💳 The company reported a significant debt level with $30.9 billion in long-term debt at the end of 2025 compared to $7.7 billion in cash.

🩺 Investors should monitor persistent expense escalation which might weigh on margin growth despite strong operational performance.

🔍 Other medical space stocks like Catalyst Pharmaceuticals, Enovis, and USANA currently hold higher Zacks Ranks #1 (Strong Buy).

🚀 The Zacks Top 10 Stocks portfolio has gained +2,530.8% since inception in 2012, significantly outperforming the S&P 500.

Bullish Signals
  • CI shares lost only 3.4% YTD vs industry decline.
  • Trades at forward P/E of 8.61x, below industry average.
  • Beat earnings estimates for four trailing quarters.
  • Adjusted income from operations rose 4% year-over-year.
  • Evernorth Health Services revenues increased 16% to $235B.
  • Repurchased 11.9M shares for $3.6B in 2025.
  • Quarterly dividend raised to $1.56 per share in 2026.
  • Maintains A Value Score and Zacks Rank #3 (Hold).
  • New model lowers out-of-pocket costs starting in 2027.
Risk Factors
  • 2024-2025 benefit expenses surged 27% and 12% due to higher medical costs.
  • Deteriorating margins as the 2025 medical cost ratio hit 84.4%.
  • Long-term debt of $30.9 billion far exceeds $7.7 billion cash reserves in 2025.
  • High leverage will continue to suppress interest expense relief going forward.
  • Shares dropped 3.4% YTD despite outperforming the sector's 13.5% decline.
Bullish Signals
  • CI shares have lost only 3.4% year-to-date, significantly outperforming the industry's average 13.5% decline.
  • The company trades at a forward P/E ratio of 8.61x, which is well below the industry average of 13.45x, indicating an attractive valuation.
  • Cigna has beat earnings estimates in each of the trailing four quarters with an average surprise of 2.7%.
  • Adjusted income from operations rose 4% year-over-year to 2025, driven by strong growth in the Evernorth Health Services segment.
  • Evernorth Health Services 2025 adjusted revenues increased 16% year-over-year to $235 billion.
  • The company successfully repurchased 11.9 million shares for approximately $3.6 billion in 2025 to support shareholder value.
  • The board increased the quarterly dividend to $1.56 per share in early 2026, up from $1.51 in 2025, signaling confidence in cash flow.
  • Cigna maintains a Value Score of A and holds a Zacks Rank #3 (Hold), suggesting solid prospects.
  • New transformative pharmacy benefits model will lower out-of-pocket costs by passing manufacturer discounts directly to customers starting in 2027.
Risk Factors
  • The company's total benefits and expenses escalated significantly, witnessing a year-over-year increase of 27% in 2024 and 12% in 2025 due to higher pharmacy, medical costs, and other benefit expenses.
  • The persistent escalation of expenses might weigh on the company's margin growth, with the medical cost ratio deteriorating 120 basis points year over year to 84.4% in 2025.
  • Cigna has been grappling with a significant debt level, holding long-term debt of $30.9 billion at the end of 2025, which is significantly higher than its cash balance of $7.7 billion.
  • The elevated leverage level is likely to keep pressure on the company's interest expenses going forward.
  • Cigna's shares have lost 3.4% year to date (YTD), even though they outperformed the industry's average 13.5% decline, suggesting relative weakness within a bearish sector.
Slightly Bullish +25

CVS vs Cigna: Which Healthcare Giant Belongs in Your Retirement Portfolio?

📈 Cigna shows 73% net income growth with consistent quarterly earnings beats.

💰 CVS offers a 3.5% dividend yield but faces recent earnings declines.

🏛 Long-term investors favor Cigna, while retirees may prefer CVS's high yield.

📊 CVS Health trades at an 11.3x trailing adjusted earnings multiple compared to Cigna's 9.4x.

💰 CVS offers a 3.5% dividend yield with $2.66 in annualized dividends, while Cigna yields roughly 2.3%.

⚠️ CVS net income fell 62.55% year-over-year due to a $5.7B goodwill impairment and litigation charges.

📈 Cigna reported strong net income growth of 73.47% in FY2025, reaching $5.957 billion.

🏥 CVS Health Care Benefits segment faces a turnaround as operating income fell 45.28%.

💼 Cigna has beaten adjusted EPS estimates in all four quarters of 2025 with consistent execution.

📉 Cigna's Evernorth pharmacy business saw 17% revenue growth and expanded to 123.6 million customers.

💹 CVS generated $10.639 billion in operating cash flow for FY2025 compared to Cigna's guidance of at least $9.0 billion for the same period.

🔄 Over the past decade, Cigna has returned over 100% to shareholders versus just 1.84% for CVS.

📉 Cigna repurchased approximately $3.6 billion worth of shares in 2025 to shrink its share count.

🛒 CVS same-store prescription volume rose 9.7% while Pharmacy & Consumer Wellness revenue grew 12.4%.

🏃‍♂️ Cigna improved its SG&A ratio significantly from 5.9% to 5.0% year-over-year.

📉 While CVS stock is up 17.32% recently, Cigna stock has declined by 14.51% over the same period.

🎯 For long-term wealth building (10-15 years), Cigna is viewed as a stronger holding due to capital discipline.

⚖️ Retirees prioritizing current income may prefer CVS's higher yield and potential for turnaround upside.

Bullish Signals
  • Cigna net income grew 73.47% to $5.96B in FY2025.
  • Company beat EPS estimates for all four quarters of 2025.
  • Evernorth revenue rose 17% with 123.6M pharmacy customers.
  • SG&A ratio improved significantly from 5.9% to 5.0% YoY.
  • Cigna repurchased 11.9M shares for $3.6B in 2025.
  • Ten-year shareholder returns of 101.36% outpace the average.
  • Forward P/E is attractive at 9.3x based on strong earnings.
Risk Factors
  • Net income plummeted 62.55% driven by $5.7B impairment and charges.
  • Cash flow guidance reduced from $10B to at least $9B.
  • Operating income fell 45.28% despite pharmacy momentum gains.
  • Health Care Benefits segment must stabilize amid peer lag.
  • Stock underperformed peers long-term with 1.84% vs Cigna's 101%.
Bullish Signals
  • Cigna (CI) reported strong net income growth of 73.47% year-over-year, reaching $5.957 billion in FY2025.
  • The company demonstrates consistent execution by beating adjusted EPS estimates in all four quarters of 2025.
  • Cigna's Evernorth pharmacy business posted robust revenue growth of 17% in Q4 2025, with pharmacy customers expanding to 123.6 million.
  • Operating discipline is evident as the SG&A ratio improved significantly from 5.9% to 5.0% year-over-year.
  • Cigna has returned capital aggressively to shareholders by repurchasing approximately 11.9 million shares for $3.6 billion in 2025.
  • Over a long-term decade period, Cigna has compounded shareholder returns of 101.36%, far outpacing the historical average.
  • Cigna trades at an attractive valuation with forward P/E around 9.3x based on its strong earnings quality.
Risk Factors
  • CVS Health net income plummeted by 62.55% year-over-year in FY2025, a drop driven by a massive $5.7 billion goodwill impairment and approximately $1.2 billion in legacy litigation charges.
  • The company reduced its 2026 operating cash flow guidance from $10 billion to at least $9.0 billion, signaling potential financial pressure or margin deterioration ahead.
  • Operating income for CVS fell sharply by 45.28% year-over-year despite showing some pharmacy momentum.
  • While Cigna has strong growth, CVS faces a specific challenge that requires proving its Health Care Benefits segment can stabilize before becoming a stronger holding.
  • CVS stock is down significantly relative to peers in the long term over a decade, having returned just 1.84% compared to Cigna's 101.36%, which may indicate structural underperformance.
Bullish +75

The Cigna Group (CI) CEO Change Timing May Come As Surprise to Some Investors, According to Barclays

📈 CI trades at $269.66 with 23.67% upside despite a >15% annual decline.

👤 CEO Cordani steps down March 2026, succeeded by experienced CFO Evanko.

💹 Earnings outlook holds strong with ≥$30.25/share and sector outperformance.

- 📈 The Cigna Group (NYSE: CI) is currently trading at $269.66 with a projected 23.67% upside potential despite falling more than 15% over the previous year.

- 👤 CEO David Cordani is retiring as of March 3, 2026, to be succeeded by Brian Evanko, who previously served as CFO and COO.

- 🧔 Barclays notes that Evanko was always considered the natural successor due to his extensive institutional experience within the company.

- ⏰ The leadership transition timing may surprise investors because it coincides with the start of a multi-year transformation of the company's pharmacy benefit management (PBM) model.

- 💵 Cigna reaffirmed its 2026 earnings outlook, forecasting full-year consolidated adjusted income from operations of at least $30.25 per share.

- 🏥 The company expects pre-tax adjusted income for Evernorth to be at least $6.9 billion and for Cigna Healthcare to be at least $4.5 billion.

- 📊 Nearly 85% of analysts remained bullish on the stock as of March 9, 2026, viewing the changes as a reflection of strategic continuity amid industry pressures.

- 🏆 The Cigna Group has outperformed the broader healthcare plans sector, which declined by more than 30% over the same one-year period.

- 🤖 Analysts at Insider Monkey believe that while CI is a good investment, AI stocks may hold greater promise for delivering higher returns in shorter time frames.

- 📜 Cigna operates as a leading global health services provider focused on pharmacy benefits, healthcare solutions, and care management through its subsidiaries Evernorth Health Services and Cigna Healthcare.

Bullish Signals
  • Cigna (NYSE: CI) listed as top value stock by billionaires.
  • 85% of analysts remain bullish on Cigna as of March 2026.
  • CI trades at $269.66 with 23.67% upside despite prior decline.
  • Cigna outperformed healthcare plans sector which dropped over 30%.
  • CEO Brian Evanko offers institutional experience and fresh leadership.
  • Full-year income forecast reaches at least $30.25 per share.
  • Deutsche Bank rates Cigna Buy with strong analyst support.
Risk Factors
  • CEO change coincides with PBM transformation start.
  • Analysts shifting conviction from Cigna to AI stocks.
  • Article implies Cigna offers inferior risk-adjusted returns.
  • High AI upside suggests opportunity cost for Cigna.
Bullish Signals
  • Cigna Group (NYSE: CI) is included in the list of 11 best value stocks to invest in according to billionaires.
  • Nearly 85% of analysts remain bullish on the company as of March 9, 2026.
  • Despite a stock decline of more than 15% over the previous year, CI is currently trading at $269.66 with a 23.67% upside potential.
  • Cigna has outperformed the healthcare plans sector, which declined by more than 30% over the same period.
  • The company's CEO Brian Evanko brings extensive institutional experience and is highlighted as the natural successor to CEO David Cordani.
  • Evanko will be one of the youngest CEOs in the healthcare services industry, suggesting a fresh leadership perspective.
  • Cigna reaffirmed its long-term earnings outlook with a forecast for full-year consolidated adjusted income from operations of at least $30.25 per share.
  • The company expects pre-tax adjusted income for Evernorth of at least $6.9 billion and Cigna Healthcare of at least $4.5 billion.
  • Deutsche Bank has issued a Buy recommendation on Cigna (CI).
  • Piper Sandler continues to back the company's PBS strategy, issuing a minor PT cut while maintaining support.
Risk Factors
  • The timing of the CEO change is a concern as Cigna Group begins the first year of a multi-year transformation of its pharmacy benefit management (PBM) model, which Barclays notes may come as a surprise to some investors.
  • Despite the stock being included in 'best value' lists, analyst conviction shifts towards AI stocks, with the article suggesting AI stocks may hold greater promise for delivering higher returns within a shorter time frame compared to Cigna.
  • The article promotes alternative investments by directing readers to reports on an unnamed AI stock with purported "10,000% upside potential" and other high-growth strategies, implicitly suggesting Cigna offers inferior risk-adjusted returns.
  • Cigna faces a competitive landscape where the firm explicitly acknowledges that AI stocks are viewed as more promising alternatives for investors seeking performance, highlighting a potential opportunity cost.